Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Kisunla Subject to Prior Pricing Review as It Follows Leqembi’s Footsteps
September 26, 2024
- Off-Year Debate “Won’t Progress” without Industry’s Behavioral Change: JMA Rep
September 26, 2024
- MHLW Panel Puts a Hold on Proposed Use of Abortion Pill at Clinics Without Beds
September 26, 2024
- Japan Approves Lilly’s Kisunla, Eisai’s ALS Med, Gilead’s Trodelvy, and Lots More
September 25, 2024
- NIBIOHN, Institut Pasteur Link Arms in Drug, Vaccine Research
September 24, 2024
- More Pregnant Cases Reported for COVID Meds, Panel Urges Greater Caution
September 24, 2024
- Ultragenyx’s Gene Therapy in Line for Orphan Tag in Japan
September 24, 2024
- Orphan Status Granted to Sanofi’s Venglustat and More in Japan
September 24, 2024
- Japan Pulls Sakigake Tags from Olumiant, Xevinapant
September 24, 2024
- Panelists See Legal Issue over Providers’ Refusal of People Vaccinated with Replicon Shot
September 20, 2024
- MHLW to Update Decade-Old Generic Roadmap, Add Blueprint for Biosimilars
September 20, 2024
- Japan Panel OKs 5 COVID Vaccines for NIP Use from October
September 20, 2024
- Puberulic Acid Determined as Cause of “Beni-Koji” Health Damages
September 19, 2024
- MHLW Working Group Gets into Details of Proposed Drug Supply Info System
September 18, 2024
- “Kobe Model” Offers Unique Subsidy to Diagnose Dementia, Test Eligibility for Lecanemab
September 18, 2024
- 9 LDP Leader Candidates Showcase Pharma Agendas in Campaign
September 17, 2024
- FY2025 Budget Request Would Add 7 PMDA Reviewers for Startup Consultations
September 13, 2024
- Japan Approves Meiji’s JN.1-Directed COVID-19 Vaccine
September 13, 2024
- MHLW Lays Out Updated Discussion Timeline for PMD Act Amendment
September 13, 2024
- Trodelvy Nears Japan Approval as It Sails through Panel Review
September 13, 2024
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…